Published 2 months ago • loading... • Updated 2 months ago

Orbis raises $93M to turn popular biologics into pills

Summary by biopharmadive.com

The startup is developing macrocyles, which share strengths of both small molecules and biologics, as oral medicines against “validated blockbuster biologic targets.”

10 Articles

All

Left

Center

Right

biopharmadive.com

Orbis raises $93M to turn popular biologics into pills

The startup is developing macrocyles, which share strengths of both small molecules and biologics, as oral medicines against “validated blockbuster biologic targets.”

2 months ago

Read Full Article

biopharminternational.com

With New Funding, Orbis Medicines to Develop Oral Macrocycles as Alternative to Biologic Drugs

With the new $94 million (€90 million) funding, the company will develop its pipeline of oral macrocycle drugs, nCycles, against validated biologic targets.

2 months ago

Read Full Article

Silicon Canals

Copenhagen’s drug discovery firm Orbis Medicines raises €90M

Copenhagen-based Orbis Medicines, a drug discovery company, has raised €90M in a Series A funding round, bringing its total funding to €116M. The round was led by NEA (New Enterprise Associates) with participation from Eli Lilly, Cormorant, the Export and Investment Fund of Denmark, Novo Holdings, and Forbion. In addition to the funding, Orbis Medicines has appointed Morten Graugaard as CEO, following his tenure as Executive Chair of the Board. …

2 months ago

Read Full Article

ramaonhealthcare.com

Orbis raises $93M to turn popular biologics into pills – RamaOnHealthcare

The European startup is one of several young companies developing oral macrocyclic peptides, which can slip into cells yet still interfere with protein

2 months ago

Read Full Article

MedCity News

A Startup’s €90M Financing for Oral Peptide Drugs Includes Backing from Eli Lilly

Orbis Medicines’ Series A round of funding was led by New Enterprise Associates. The startup is developing oral macrocyclic drugs for targets validated by blockbuster biologic medications that must be administered by injection. The post A Startup’s €90M Financing for Oral Peptide Drugs Includes Backing from Eli Lilly appeared first on MedCity News.

2 months ago

Read Full Article

outsourcing-pharma.com

Orbis Medicines bags €90 million Series A to develop oral competitors of biologics

Orbis Medicines secures €90M Series A to develop innovative oral macrocycles, offering cost-effective alternatives to biologic drugs and targeting chronic disease markets.

2 months ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year